SMAD3 and neoplasm: Mice with myeloid-specific overexpression of Smad3 (Lys2-Smad3-AAV9) showed significantly slower tumor progression and enhanced anti-tumor immunity, accompanied by fewer MO-MDSC and more mature MΦ and DC in both tumor tissue and spleen.